Related Experiment Video
Updated: Oct 2, 2025
Detection of Abnormal Prion Protein by Immunohistochemistry
Published on: May 5, 2023
THαβ Immunological Pathway as Protective Immune Response against Prion Diseases: An Insight for Prion Infection
Adam Tsou1, Po-Jui Chen2, Kuo-Wang Tsai3
1Department of Neurology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
Abstract:
Prion diseases, including Creutzfeldt-Jakob disease, are mediated by transmissible proteinaceous pathogens. Pathological changes indicative of neuro-degeneration have been observed in the brains of affected patients. Simultaneously, microglial activation, along with the upregulation of pro-inflammatory cytokines, including IL-1 or TNF-α, have also been observed in brain tissue of these patients. Consequently, pro-inflammatory cytokines are thought to be involved in the pathogenesis of these diseases. Accelerated prion infections have been seen in interleukin-10 knockout mice, and type 1 interferons have been found to be protective against these diseases. Since interleukin-10 and type 1 interferons are key mediators of the antiviral THαβ immunological pathway, protective host immunity against prion diseases may be regulated via THαβ immunity. Currently no effective treatment strategies exist for prion disease; however, drugs that target the regulation of IL-10, IFN-alpha, or IFN-β, and consequently modulate the THαβ immunological pathway, may prove to be effective therapeutic options.
Insights
Prion diseases involve neurodegeneration and inflammation. Modulating the THαβ immune pathway with therapies targeting IL-10 and interferons may offer effective treatments for these devastating conditions.
Area of Science:
- Neuroscience
- Immunology
- Infectious Diseases
Background:
- Prion diseases, such as Creutzfeldt-Jakob disease, are fatal neurodegenerative disorders caused by infectious proteins.
- Neuroinflammation, characterized by microglial activation and pro-inflammatory cytokine release (e.g., IL-1, TNF-α), is a hallmark of prion disease pathology.
- Existing treatments for prion diseases are lacking, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of the THαβ immunological pathway in prion disease pathogenesis.
- To explore the potential of modulating specific immune mediators, like interleukin-10 (IL-10) and type 1 interferons (IFN-α/β), as therapeutic targets.
Main Methods:
- Review of existing literature on prion disease pathology and host immune responses.
- Analysis of findings from interleukin-10 knockout mouse models exhibiting accelerated prion infections.
- Examination of the protective effects of type 1 interferons in prion disease models.
Main Results:
- Pro-inflammatory cytokines are implicated in the pathogenesis of prion diseases.
- Interleukin-10 knockout mice show accelerated prion infections, suggesting a protective role for IL-10.
- Type 1 interferons (IFN-α/β) demonstrate protective effects against prion diseases.
- Interleukin-10 and type 1 interferons are key components of the antiviral THαβ immune pathway.
Conclusions:
- Host immunity against prion diseases may be regulated through the THαβ immunological pathway.
- Therapeutic strategies targeting the regulation of IL-10, IFN-α, and IFN-β could offer a promising avenue for treating prion diseases.
- Modulating the THαβ pathway presents a potential therapeutic approach for prion diseases due to the absence of effective treatments.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
01:40Cell-mediated Immune Responses